What Happened to Science.bio? Closure Timeline

The closure announcement

Science.bio emailed its customer list on January 27, 2026 to say it was closing. A thread on the Rapamycin News forum was opened the same afternoon by recipients, who posted the email text and discussed what it meant for ongoing work. That thread is the reason the date is pinned as precisely as it is — the company's own notice does not carry one.

The site did not go dark. It was replaced with a standing notice, which is still being served. We requested it on July 31, 2026 and received a single page titled “Science Bio — Permanently Closed”, reading in part:

“After careful consideration, Science.bio has made the decision to permanently close and discontinue the sale of research products.”

That is the entirety of the company's public explanation. No date, no cause, no successor.

What the closure email said

We are not republishing the email in full — the forum thread above holds the original wording, posted by people who actually received it. As reported there, the substance was:

• The closure was permanent and immediate, not a pause or a rebrand. Recipients quote the opening line as “It is with a heavy heart that we announce Science.bio will be permanently closing today.”
• On orders: “All outstanding orders will be either fulfilled or fully refunded.”
• On the reason: recipients quote the email as citing regulatory compliance. We could not independently verify the email text, and the public notice gives no reason, so we treat this as a report from customers rather than a confirmed fact.

We have deliberately not turned that last point into a claim about any regulator's conduct. A company saying it is closing for compliance reasons is not the same as a regulator having acted, and we have no verified record of the latter. If you want the enforcement record itself, the FDA publishes warning letters and actions at fda.gov.

Timeline

• January 27, 2026. Science.bio emails customers announcing permanent closure. The Rapamycin News thread is opened the same day, at 1:22pm, archiving the email.
• After the announcement. The storefront is replaced by a standing closure notice. Per the email, outstanding orders are to be fulfilled or fully refunded; we have no way to audit individual outcomes and make no claim about them.
• July 31, 2026. The closure notice is still being served, now including an explicit warning about impersonators. No successor entity has been announced.

An earlier version of this page carried a more detailed month-by-month timeline, including specific refund-processing windows and a store-credit policy. We removed those entries because we could not trace them to a source. It also referenced a specific social-media post as a citation; we could not verify that post exists, so it is gone too.

If you still have money tied up

The notice on science.bio lists a customer support email address, and that is the right first stop for an unresolved balance. If you paid by card and cannot get a response, your card issuer's dispute process is the normal fallback — those windows are shorter than most people assume, so it is worth checking yours now rather than later. Any credit you held with Science.bio is specific to that account and cannot be transferred to another vendor, including us.

How this compares to the Peptide Sciences closure

The two closures are often discussed together, and the comparison is genuinely useful — but only on the parts that are documented. Both companies stopped selling research products in the first half of 2026. Both left their domains up and replaced the storefront with a notice. Both published near-identical warnings that anyone claiming successor status is unauthorised, which tells you something about how quickly impersonation follows a well-known vendor's exit.

The visible difference is what customers were told. Science.bio emailed its list, stated the closure was permanent, and addressed outstanding orders directly. Peptide Sciences published a notice describing its shutdown as voluntary but did not publish a date, a reason, or an orders process. Beyond that, we do not draw conclusions about either company's circumstances, because the public record does not support them.

Where researchers went next

Science.bio's audience overlapped heavily with longevity, nootropic and biohacking research. The immediate problem for that group was continuity: most projects run on a small set of compounds, and a supply gap stalls the timeline. Replacement-vendor discussion since has converged on three practical criteria — coverage of the same compounds, per-batch certificates of analysis published on the product page rather than on request, and domestic fulfilment with visible per-unit pricing.

Pure U.S. Peptides was built around that posture. We carry the longevity workhorses — MOTS-c, NAD+, BPC-157, TB-500 — plus the Selank/Semax nootropic pair and Epithalon (also written Epitalon), with public per-batch COAs and U.S. fulfilment. Side-by-side comparison: Science.bio alternatives.

Migration checklist

1. Resolve any outstanding Science.bio balance through the support address on their notice, and check your card dispute window before it closes.
2. List the three to five compounds you actually reorder. That list, not catalog size, is what determines whether a vendor works for you.
3. Pull the lot-specific certificate of analysis for each replacement compound and check it against your previous purity baseline.
4. Run one small order to validate purity and shipping before consolidating your supply.
5. Treat any “Science.bio is back” domain as fraudulent — the company itself says so, and asks that you report it.

Sources

• science.bio — the company's own closure notice, retrieved July 31, 2026.
• Rapamycin News forum thread — “Science.bio closes,” opened January 27, 2026, where recipients archived the closure email.
• FDA warning letter database — the primary enforcement record, searchable directly.